March 21, 2019
MIPS unable to replicate new WaveCel helmet technology performance claims
Media
March 21, 2019
Orexo publishes the Annual Report for 2018
March 21, 2019
MIPS comments communication from Bontrager regarding new technology in some of its helmet models
March 20, 2019
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
March 19, 2019
Altimmune Announces Positive Results from NasoVAX Extension Study
March 14, 2019
Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology
March 13, 2019
BONESUPPORT™ launching a new product – BONIFY™ – US product portfolio expansion
March 11, 2019
Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
March 11, 2019
Modus Therapeutics strengthens management team with appointment of Mats Blom, MBA as CFO
March 04, 2019
Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO)